Back to search
Anaplastic Astrocytoma, IDH-Wildtype
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Anaplastic Astrocytoma, IDH-Wildtype trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Anaplastic Astrocytoma, IDH-Wildtype trials you may qualify forThe primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (…
This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-hist…
A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent results…
This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of hi…
This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer…